Document is current
Any future updates will be listed below
-
Authors
Friberg, Susanna
Lindblad, Caroline
Zeiler, Frederick A.
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Granberg, Tobias
Svenningsson, Per https://orcid.org/0000-0001-6727-3802
Piehl, Fredrik https://orcid.org/0000-0001-8329-5219
Thelin, Eric P. https://orcid.org/0000-0002-2338-4364
- License Information
-
More Information
Article History
Accepted: 10 September 2024
First Online: 3 October 2024
Competing interests
: S.F., C.L., F.A.Z., T.G. and E.P.T. have nothing to disclose. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio and Roche and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). P.S. is serving in a DSMB for Lundbeck and in advisory boards for AbbVie and Takeda. F.P. has received research grants from Janssen, Merck KGaA and UCB and fees for serving on the data monitoring committee in clinical trials with Chugai, Lundbeck and Roche, has prepared an expert witness statement for Novartis and is steering committee member of the BioMS consortium.
